TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
SAN DIEGO, Aug. 29, 2017 -- Oxeia Biopharmaceuticals, Inc. has been invited to present at the 2017 Gateway Conference, which is being held on September 6-7, 2017 at the Four Seasons Hotel San Francisco.
Oxeia management is scheduled to present on Wednesday, September 6 at 2:00 pm Pacific Time, with one-on-one meetings held throughout the conference. The presentation will be webcast live and available for replay in the Investor Relations section of Oxeia’s website at www.oxeiabiopharma.com or on the Gateway Conference website at www.gateway-conference.com/presenters. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].
About the Gateway Conference
The 6th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.
About Oxeia Biopharmaceuticals, Inc.
Oxeia Biopharmaceuticals, Inc. is a privately held clinical stage biotechnology company headquartered in San Diego, CA. The company is focused on developing treatments for concussions and other acute neurotrauma conditions. Oxeia’s lead program, OXE-103, uniquely targets the metabolic dysfunction and subsequent neurotrauma underlying acute concussion pathophysiology. Oxeia anticipates initiating Phase 2 studies for OXE-103 in concussion and additional neurological indications in early 2018. The program has maintained a strong safety profile across nine previous clinical studies totaling 345 patients.
Contact: Kartik Shah Chief Business Officer Oxeia Biopharmaceuticals, Inc [email protected] 207.232.2863 Marek Ciszewski, J.D. Liolios, Inc. [email protected] 949.574.3860
